Uppsala,
The data indicates that the use of OssDsign Catalyst leads to consistent and rapid bone healing and remodeling, with improved patient outcomes as a result. They also confirm the previously reported best-in-class pre-clinical results achieved in the most demanding preclinical model for spinal fusion - the BODEN model.
"I am very encouraged to see the solid consistency between the clinical results in TOP FUSION, the previously published first in-patient case report and our pre-clinical data. The successful outcome of this first important clinical study marks a pivotally important milestone for OssDsign Catalyst and will boost our efforts to establish our unique nanosynthetic bone graft on the U.S. market," says
TOP FUSION is a first-in-patient open-label, prospective, single-center clinical study led by Dr Péter Pál Varga and Dr Àron Lazary at the
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body.
About Top Fusion
The clinical study TOP FUSION (NCT05114135) was initiated in
This disclosure contains information that
CEO
+46 18 55 39 93
morten.henneveld@ossdsign.com
https://news.cision.com/ossdsign-ab/r/ossdsign-reports-exceptional-data-from-the-clinical-study-top-fusion,c3906366
https://mb.cision.com/Main/18020/3906366/2529791.pdf
(c) 2024 Cision. All rights reserved., source